Is Alembic Pharmaceuticals a Good Buy After Its Q1 FY27 Results?

The Alembic Pharmaceuticals share price has been under the spotlight this results season after the company reported its first-quarter numbers for FY27. Alembic Pharmaceuticals is a pharmaceutical company with domestic formulations and export generics businesses, and its Q1 FY27 print, for the quarter ended June 30, 2026, gives investors a fresh data point to test whether the stock still deserves a place in a portfolio at current levels.

Revenue for the quarter came in at Rs 2,165 crore, up 26.1% year on year, while profit after tax came in at Rs 172 crore, up 12.2% from a year earlier. That combination of numbers is exactly what this article breaks down, along with what it means for the Alembic Pharmaceuticals share price from here.

This piece works through the quarter's financial highlights, the business factors behind the numbers, where the Alembic Pharmaceuticals share price stands against its 52-week range and valuation multiples, and the key risks worth watching before treating this as a buy, hold or a stock to avoid for now.

Click Here – Get Free Investment Predictions

Alembic Pharmaceuticals Q1 FY27 Financial Highlights

Metric	Q1 FY27	Q1 FY26	YoY Change
Revenue	Rs 2,165 crore	Rs 1,717 crore	26.1%
EBITDA	Rs 347 crore	Rs 288 crore	20.5%
Operating Margin	16.1%	16.8%	NA
Profit Before Tax	Rs 222 crore	Rs 190 crore	16.7%
Net Profit / (Loss)	Rs 172 crore	Rs 154 crore	12.2%

Alembic Pharmaceuticals Q1 FY27 Performance Analysis

Check Alembic Pharmaceuticals Fundamentals on Univest Screener

Revenue growth of 26.1% for the quarter came from steady demand across the company's core business, keeping the topline trend intact for the pharmaceuticals sector.

Profitability moved broadly in line with revenue this quarter, with PAT at Rs 172 crore against Rs 154 crore a year earlier. There is no major surprise in either direction, and the Alembic Pharmaceuticals share price has traded accordingly, without a sharp re-rating either way.

On a sequential basis, revenue moved up 15.6% sequentially from Rs 1,873 crore in the March 2026 quarter and net profit moved down 14.5% sequentially from Rs 202 crore in the prior quarter, giving a fuller picture of the trend behind the Alembic Pharmaceuticals share price than the year on year comparison alone.

Key Business Factors in Q1 FY27

Revenue Trend

Alembic Pharmaceuticals's revenue grew 26.1% year on year this quarter, taking the quarterly base to Rs 2,165 crore in a pharmaceuticals business that remains sensitive to demand and pricing cycles that ultimately feed through to the Alembic Pharmaceuticals share price.

Margin Movement

EBITDA rose 20.5% to Rs 347 crore, and operating margin moved to 16.1% from 16.8% a year earlier, a sign that cost control or pricing held up during the quarter.

Balance Sheet Position

Alembic Pharmaceuticals carries a low debt-to-equity ratio of 0.25, giving it a conservative balance sheet heading into the rest of FY27.

Valuation Context

The stock trades at a PE of 23.8x, below the industry average of 38.1x, which is worth factoring into any read of whether the Alembic Pharmaceuticals share price is expensive or reasonably priced.

Dividend Details

No interim dividend was declared alongside Alembic Pharmaceuticals's Q1 FY27 results. The stock currently carries a trailing dividend yield of 1.44%, based on dividends paid over the last year. Investors tracking the Alembic Pharmaceuticals share price for income should watch the company's announcements around its next annual results for any dividend decision.

Alembic Pharmaceuticals Share Price Outlook for FY27

Alembic Pharmaceuticals's FY27 outlook looks steady rather than dramatic based on this quarter's numbers. Investors should watch for any change in margin trend or demand commentary from management in the next results for a clearer signal on where the Alembic Pharmaceuticals share price heads from here.

Without a major catalyst in either direction, the Alembic Pharmaceuticals share price is likely to keep tracking the company's quarterly execution more than any single headline number.

Alembic Pharmaceuticals Stock Performance

Download the Univest iOS App or Univest Android App to track Alembic Pharmaceuticals's live share price and get daily stock updates.

The Alembic Pharmaceuticals share price was trading around Rs 844 as results season played out in late August 2026, roughly 15.4% below its 52-week high of Rs 998 and well above its 52-week low of Rs 636. Promoter holding stood at 69.9% as of the June 2026 quarter.

The Alembic Pharmaceuticals share price has moved without much drama on this result, consistent with a quarter that did not materially change the investment case either way. On profitability ratios, the company reports a return on equity of 11.89% and a book value of around Rs 289 per share, both useful reference points when judging whether the current price is reasonable.

Key Risks

Sector and Demand Risk

As a pharmaceuticals business, Alembic Pharmaceuticals's results remain tied to sector-specific demand, pricing and regulatory cycles that can shift from quarter to quarter and move the Alembic Pharmaceuticals share price well before the next result.

Execution Risk

Sustaining this quarter's trend into the rest of FY27 depends on management execution on costs, pricing and demand, none of which are guaranteed.

Conclusion

Alembic Pharmaceuticals's Q1 FY27 results were steady rather than exciting, with revenue at Rs 2,165 crore and PAT at Rs 172 crore. The Alembic Pharmaceuticals share price does not present a strong case either to buy aggressively or to avoid the stock based on this quarter alone, and investors should track the next result for a clearer trend.

Frequently Asked Questions on Alembic Pharmaceuticals Q1 FY27 Results

What were Alembic Pharmaceuticals's Q1 FY27 results?

Ans. Alembic Pharmaceuticals reported Q1 FY27 revenue of Rs 2,165 crore, up 26.1% year on year, and PAT of Rs 172 crore, up 12.2% year on year.

Is Alembic Pharmaceuticals a good buy after its Q1 FY27 results?

Ans. Alembic Pharmaceuticals's results were largely in line with expectations this quarter, so the case to buy or avoid rests more on the broader trend than on this single print. Investors should form their own view based on their own risk appetite and time horizon.

What is the Alembic Pharmaceuticals share price today?

Ans. The Alembic Pharmaceuticals share price was trading around Rs 844 in late August 2026, about 15.4% below its 52-week high of Rs 998 and well above its 52-week low of Rs 636.

What is Alembic Pharmaceuticals's revenue and profit for Q1 FY27?

Ans. Alembic Pharmaceuticals reported revenue of Rs 2,165 crore and a net profit of Rs 172 crore for the quarter ended June 30, 2026.

Did Alembic Pharmaceuticals declare a dividend with its Q1 FY27 results?

Ans. No interim dividend was declared alongside Alembic Pharmaceuticals's Q1 FY27 results. Investors should track the company's next annual results for any dividend announcement.

What is Alembic Pharmaceuticals's PE ratio and is it expensive?

Ans. The Alembic Pharmaceuticals share price trades at a trailing PE of 23.8x, against an industry average of 38.1x. Investors should compare this with the company's growth rate before judging value.

What are the key risks for Alembic Pharmaceuticals investors right now?

Ans. As a pharmaceuticals business, Alembic Pharmaceuticals's results remain tied to sector-specific demand, pricing and regulatory cycles that can shift from quarter to quarter and move the Alembic Pharmaceuticals share price well before the next result. Sustaining this quarter's trend into the rest of FY27 depends on management execution on costs, pricing and demand, none of which are guaranteed.

What is Alembic Pharmaceuticals's promoter shareholding?

Ans. Promoter holding in Alembic Pharmaceuticals stood at 69.9% as of the June 2026 quarter.